Torrent Pharmaceuticals Limited

TORNTPHARM

INE685A01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:15:49 2024-05-23 EDT			5-day change	1st Jan Change
2,692 ^INR	+0.91%		+1.55%	+16.78%

05-14	Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	RE
04-30	Torrent Pharmaceuticals Limited Receives an Order from Deputy Commissioner of State Tax, Guwahati -A-99, Guwahati, Assam, Imposing a Penalty of INR 3,39,842	CI

Torrent Pharmaceuticals Limited Appoints Nayantara Bali as an Independent Director, Effective March 07, 2019

March 08, 2019 at 08:09 am

Torrent Pharmaceuticals Limited announced that Ms. Nayantara Bali has been appointed as an Independent Director for a for a term of 3 years effective from 07 March 2019. She is not related to any other Director of the company. She currently serves as the Director with ANV Consulting Pte. Ltd. Singapore.

Latest news about Torrent Pharmaceuticals Limited

Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	05-14	RE
Torrent Pharmaceuticals Limited Receives an Order from Deputy Commissioner of State Tax, Guwahati -A-99, Guwahati, Assam, Imposing a Penalty of INR 3,39,842	04-30	CI
Torrent Pharmaceuticals Limited Receives Order from Deputy Commissioner State Tax, Special Circle 1, Kunchanapalli, Andhra Pradesh	04-23	CI
Torrent Pharmaceuticals Limited Receives Order Passed by Deputy Commissioner of State Tax, Ropar Division, Punjab Imposing Penalty	04-19	CI
Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60	04-08	CI
Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024	04-01	CI
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director	02-29	CI
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy	02-08	MT
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	02-05	MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy	02-05	MT
Torrent Pharmaceuticals Posts Gains in Fiscal Q3 Consolidated Net Profit	02-04	MT
Torrent Pharmaceuticals' Consolidated Profit in Fiscal Q3	02-02	MT
Transcript : Torrent Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 02, 2024	02-02
India's Torrent Pharma posts higher Q3 profit on strong domestic demand	02-02	RE
Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024	02-02	CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-02	CI
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO	01-23	RE
Torrent Pharmaceuticals Forms New Wholly-Owned Arm in Colombia	01-04	MT
Torrent Pharmaceuticals' Oral Oncology Plant Gets Fives Observations from US FDA	12-11	MT
Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited Enter into Licensing and Supply Agreement to Co-Market, Saroglitazar Mg	11-10	CI
Nomura Adjusts Torrent Pharmaceuticals Price Target to INR2,156 From INR2,199, Keeps at Buy	23-10-25	MT
Torrent Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q2; EPS, Revenue Meet Estimates	23-10-24	MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,040 From INR1,950, Keeps at Hold	23-10-24	MT
Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences	23-10-24	CI
Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative	23-10-23	CI

Chart Torrent Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Q4 2024 Earnings Release

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Torrent Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,692 INR

Average target price

2,737 INR

Spread / Average Target

+1.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TORRENT PHARMACEUTICALS LIMITED	+16.78%	10.84B
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals